TRENDING TOPICS AND NEWS IN HCT AND CELLULAR THERAPY

Topics to Explore

MRD

Read the latest insights related to MRD, or "measurable residual disease". Detecting and monitoring MRD is crucial in assessing the effectiveness of treatment and predicating likelihood of disease reoccurrence.

MRD

Daratumumab plus lenalidomide vs. lenalidomide alone for post-transplant maintenance therapy in newly diagnosed MM

by Blood Advances

Findings from the Phase 3 AURIGA trial support the use of lenalidomide plus daratumumab (D-R) over lenalidomide alone (R) as post-transplant maintenance therapy for patients with newly diagnosed...

MRD

Dara-KRd induction and consolidation with double ASCT for high-risk NDMM

by Blood

Researchers have identified an intensive treatment to benefit individuals with newly diagnosed multiple myeloma (NDMM) who qualify for stem cell transplantation but face unfavorable outcomes due...

MRD

Mutational screening for early relapse prediction post-transplantation

by Blood

Relapse after achieving complete remission (CR) is the leading cause of death following allogeneic stem cell transplantation

MRD

CD19 CAR T-cell therapy and LTFU for relapsed/refractory CLL

by ASTCT Science Highlights

The results of a Phase I/II clinical trial found that CD19-targeted chimeric antigen receptor-modified (CD19 CAR) T-cell therapy led to long-term durable responses in a subgroup of patients with...

MRD

Ultrasensitive chimerism after allo-HCT to augment MRD data

by ASTCT Science Highlights

A proof-of-concept test of an ultrasensitive assay validated the post-allogeneic hematopoietic cell transplantation (allo-HCT) measurement of chimerism to increase measurable residual disease...

MRD

High Concordance Seen Between MRD Measurement by MFC and FGT in Infants with KMT2A-r ALL

by Eleanor Mayfield, ELS

In infants with acute lymphoblastic leukemia (ALL) associated with KMT2A gene rearrangements, measurement of MRD by multicolor flow cytometry (MFC) and by PCR for fusion gene transcripts (FGT) had...